COVID-19 Vaccine Antigenicity in the Setting of MS Disease Modifying Treatments
Background: Although FDA-approved COVID vaccines prevent severe infections in the general population, their efficacy in the face of immune...
Lowered COVID-19 mRNA Vaccine Antibody Response in MS Patients Treated with B -Cell Depleting and S1P-Receptor-Targeting Therapies Compared to Controls: An Interim Analysis
Background: There are two mRNA vaccines targeting the SARS-CoV2 virus widely used in the U.S. There is limited knowledge about SARS-CoV2...